大紀事

The decision of the AMS BioteQ Board of Directors to establish a branch office in Tokyo, Japan and appoint a representative for the branch office.

Announcement of the Board Resolution of AMS BioteQ Regarding the Convening of the 113th Annual Shareholders' Meeting

The board of directors of AMS BioteQ has resolved to issue common shares by way of a private placement.

AMS BioteQ was invited to exhibit at the inaugural Japan Pharmaceutical Exhibition.

"Artificial Dressing and Its Application for Promoting Wound Healing" "patent approved by the United States Patent and Trademark Office."

Signed a memorandum of understanding (MOU) on industry-academic collaboration with the School of Pharmacy, Kaohsiung Medical University, to enhance industry-academic exchanges.

The capital increase case for the year 112, with a fund of 75 million NTD, has been fully subscribed, and the capital increase base date is set on 1st February.

"Artificial Dressing and Its Application for Promoting Wound Healing" has successfully obtained approval for a new invention patent in Taiwan.

SIPSIP™ Foam, the AMS BioteQ wound dressing, has successfully obtained FDA registration.

SIPSIP™ Foam successfully obtained the TFDA medical device approval.

Debuted SIPSIPᵀᴹ Series dressing at Medical Japan 2023 Tokyo.

Collaboration with Kaohsiung Medical University and Thailand's Chulalongkorn University for the development of inhibiting Dengue virus DENV-2 experiment.

Issued the first employee stock warrants in 2023.

Collaboration with Kaohsiung Medical University and Mahidol University (Thailand) to develop anti-avian influenza drugs.

Setting up the Quality Management System (QMS).

Setting up the Audit and Compensation Committees, and listing on the Emerging Stock Market.

Issued the first employee stock warrants for 10M (NTD) in 2021.

The stocks were entirely replaced without physical certificates.

Implemented a cash capital increment of 90M (NTD), leading to an augmented paid-in capital of 250M (NTD) subsequent to the increment.

IPO to Taipei Exchange: Stock Symbol 6864

Announced collaboration with National Taiwan University College of Medicine for testing YUAN-03 in prevention and treatment of SARS-CoV-2. At the effective dose of 75ppm, the virus inhibition rate is almost 100%.

Announced collaboration with the Institute of Biotechnology and Pharmaceutical Research, NHRI. Passed testing against HCoV-OC43 with 50ppm effective dose, achieving 100% virus inhibition rate.

Implemented a cash capital increment of 80M (NTD), leading to an augmented paid-in capital of 160M (NTD) subsequent to the increment.

Awarded the subsidy for the project 'Development of Hydrogel Spray with Natural Antimicrobial High Polymer Material,' granted by the Ministry of Economic Affairs, under the SBIR P1 program.

Awarded the subsidy for the project 'Development of Feed Additive Using Edible Probiotic Fermentation Technology,' granted by the Ministry of Economic Affairs, under the SBIR S1 program.

Awarded the subsidy for the project 'Development of Immune-Modulating Feed Additives Using Edible Probiotic Technology', granted by the Industrial Development Administration, Ministry of Economic Affairs, under the CITD program.

Formation of RD base in Southern Taiwan Science Park.

Implemented a cash capital increment of 79.95M (NTD), leading to an augmented paid-in capital of 80M (NTD) subsequent to the increment.

Successfully transferred technology from National Chung Hsing University for the formulation and production method of Streptomyces Padanus PMS-702 for plant protection.

Formation of AMS BioteQ Co., Ltd.